Loading
Bladder and Urothelial Cancer Treatments · Journal article
Frontiers in Molecular Biosciences · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study in a murine orthotopic bladder cancer model showing that concurrent blockade of the ErbB pathway enhances the efficacy of intravesical interferon-alpha gene therapy, with improved median overall survival in treated animals. The work identifies a putative resistance mechanism and provides rationale for clinical combination trials, but remains at the hypothesis-generating stage and does not yet warrant changes to clinical practice.
Randomized preclinical syngeneic orthotopic murine bladder cancer model with in vitro supporting studies. Mice bearing syngeneic MB49 orthotopic bladder tumors; specific age, sex, and strain information not provided in abstract.. Intervention: Combination intravesical lentiviral interferon-alpha gene therapy (LV-IFNα) plus oral afatinib (pan-ErbB receptor family blocker). Compared with: Vehicle control, LV-Ctrl alone, LV-IFNα alone, and LV-Ctrl/Afa combination.
Combination LV-IFNα/Afa significantly reduced MB49 cell viability in vitro compared to all other treatment conditions Median overall survival with LV-IFNα/Afa was 49 days versus 15 days (Ctrl), 14 days (LV-Ctrl), 29 days (LV-IFNα), and 26 days (LV-Ctrl/Afa); log-rank p 0.001 Combination treatment markedly inhibited cell migration in vitro
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is preclinical and does not directly inform clinical practice at present. It provides mechanistic rationale for a future clinical trial combining intravesical IFN-α gene therapy with an ErbB pathway inhibitor in patients with BCG-unresponsive NMIBC, but human data are required before any change to current therapeutic recommendations.
Preclinical murine model study identifying a putative resistance mechanism and demonstrating proof-of-concept for combination therapy, but requiring clinical translation and validation.
As stated by the source record.
Quoted from the source exactly as published.
This work is preclinical and does not directly inform clinical practice at present. It provides mechanistic rationale for a future clinical trial combining intravesical IFN-α gene therapy with an ErbB pathway inhibitor in patients with BCG-unresponsive NMIBC, but human data are required before any change to current therapeutic recommendations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction Intravesical interferon-alpha (IFNα) gene therapy is approved by the FDA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Identifying resistance mechanisms and deploying targeted combination treatment strategies is a rational approach to improving treatment responses. We identified the ErbB pathway as a resistance mechanism to IFNα gene therapy, and we hypothesized that combination treatment with an ErbB pathway blocker and IFN-α could improve outcomes in resistant tumors. Methods Murine bladder cancer cells were treated in vitro with lentiviral IFNα (LV-IFNα) gene therapy, with/without afatinib (Afa), a pan-ErbB inhibitor, and cell viability and migration assays were performed. In vivo studies were conducted in a syngeneic MB49 orthotopic murine bladder cancer model, and mice were randomized into five treatment groups and treated with single treatments: Ctrl (vehicle), LV-Ctrl, LV-IFNα, and combination treatments with LV-Ctrl/Afa or LV-IFNα/Afa. Results Combination therapy with LV-IFNα/Afa significantly reduced MB49 cell viability in vitro compared to all other treatment conditions. This additive effect on cell viability appeared to be driven by a combination of early-cytostatic and late-cytolytic effects. The combination treatment also markedly inhibited cell migration. Finally, the in vivo studies demonstrated improved overall survival (OS) with LV-IFNα/Afa (median OS was 49 days in the LV-IFNα/Afa group vs. 15, 14, 29, and 26 days in Ctrl, LV-Ctrl, LV-IFNα, and LV-Ctrl/Afa groups, respectively; log-rank p 0.001). Conclusion Our findings suggest that the ErbB pathway may serve as a clinically actionable resistance mechanism to intravesical IFNα gene therapy and, when targeted concurrently, it may improve treatment efficacy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.